Investigation on the safety and utility of apremilast for the treatment of refractory rash in patients with dermatomyositis Investigation on the safety and utility of apremilastfor the treatment of refractory rash in patient ...
Investigation on the safety and utility of apremilast for the treatment of refractory rash in patients with dermatomyositis - ACDM Investigation on the safety and utility of apremilastfor the treatment of refractory rash in patient ...
Oral administration of apremilast: Start with 10 mg of oral dose and gradually increase the dose until day 5, 30mg twice a day from day 6 (morning / evening) for a total of 12 weeks Oral administration of apremilast: Start with 10 mg of oral dose and gradually increase the dose unt ...
Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis Evaluating Safety & Efficacy of Apremilastin the Treatment of Cutaneous Disease in Patients With Rec ...
A Phase 2, Open Label Single Arm Study for Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis A Phase 2, Open Label Single Arm Study for Evaluating Safety & Efficacy of Apremilastin the Treatmen ...
A Study to Evaluate the Safety and Efficacy of Apremilast in the Treatment of Skin Disease in Patients With Dermatomyositis A Study to Evaluate the Safety and Efficacy of Apremilastin the Treatment of Skin Disease in Patient ...
An Open Label Study Evaluating the Safety and Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Dermatomyositis An Open Label Study Evaluating the Safety and Efficacy of Apremilastin the Treatment of Cutaneous Di ...